The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule

Benedict C. S. Cross(University of Cambridge), Heather P. Harding(University of Cambridge), Ian R. Baxendale(Durham University), Babal K. Jha(Cleveland Clinic), Robert H. Silverman(Cleveland Clinic Lerner College of Medicine), Thomas A. Neubert(New York University), David Ron(Institute for Medical Research), Paweł Sadowski(Queensland University of Technology), Peter J. Bond(Unilever (United Kingdom)), Jonathan M. Goodman(University of Cambridge), Jaroslav Žák(Scripps Research Institute)
Institute for Future Environments; Science & Engineering Faculty
January 1, 2012
Cited by 13

Related Papers

Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function
|Neuron|2015|917
An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles
|Beilstein Journal of Organic Chemistry|2013|841
The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule
|Proceedings of the National Academy of Sciences|2012|594
Predicting the mutations generated by repair of Cas9-induced double-strand breaks
|Nature Biotechnology|2018|529